[ad_1]
Regeneron, a manufacturer of antibody treatments known to have been administered after US President Donald Trump contracted the new coronavirus infection (Corona 19), was in the spotlight. On September 17, the pharmaceutical company was posted on the exterior wall of the Westchester campus building in Tarrytown, New York. The logo is displayed. Yunhap news
This week, as news that the United States Food and Drug Administration (FDA) approved the emergency use of antibody treatment for Regeneron’s Coronavirus-19 Infectious Disease (Corona 19), which was also administered by the US President Donald Trump, The market is also paying attention to whether interest in related stocks (beneficiary stocks, thematic stocks, etc.) will increase.
Two weeks ago, ‘Pfizer’, one week ago, ‘Modena’, and one after another, the company’s current COVID-19 vaccine, which is currently being developed (clinical), delivered a high prevention effect in half the 90% of the main communication media in the world. Consequently, the heightened interest from the domestic stock market or the overheating reaction towards Pfizer, Moder and related stocks has been heading one after another.
Including Regeneron news, a US news item is released at the beginning of each week for three weeks.
According to the US media on the 21st (local time), the FDA approved the emergency use of “REGN-COV2”, an antibody treatment from the US biotech company Regeneron.
The FDA has approved that the drug can be used urgently for the treatment of patients with mild or moderate symptoms, including high-risk groups 12 years and older and 65 years or older.
According to the FDA, the treatment is a combination of two monoclonal antibodies. Among the antibodies in the blood of a cure for Corona 19, only those that can neutralize the virus were selected and used as treatments.
In the comparison between real high-risk patients and the control group taking the dummy drug (placebo), it was found that the rate of hospitalization or going to the emergency room for COVID-19 symptoms within 28 days after at the beginning of the drug was reduced.
This remedy was also used in treatment at the time of the confirmation of Corona 19 by the President of the United States, Donald Trump, in October. At that time, the Gilead Science antiviral drug “amdesivir” was also administered, which also attracted attention.
At this time, he also first sparked interest in Regeneron’s actions related to Remdesivir. However, while the interest at the time was based on the choice of the White House medical staff and the degree of praise from President Trump, the difference is that this time, the basis for the approval of emergency use by the FDA.
REGN-COV2, which is classified as a monoclonal antibody treatment, is of the same type as’LY-CoV555 ‘, which is jointly developed by the American pharmaceutical company’ Eli Lily ‘and the Canadian biotechnology company’ Epselera ‘. It is also the second approval for emergency use after approval for emergency use.
Also, earlier this month, Regeneron announced plans to produce 80,000 people by the end of November and 300,000 people by the end of January next year.
